Effect of invasive aspergillosis on risk for different causes of death in older patients with acute myeloid leukaemia or high-risk myelodysplastic syndrome

Table 1 Descriptive statistics of the selected relevant variables at time of diagnosis of AML or high-risk MDS

Characteristics	n (%)
Total	806
Age (mean)	70
Age
≤70 years	427 (53)
>70 years	379 (47)
Sex
Male	441 (55)
Female	365 (45)
AML or MDS
AML	677 (84)
MDS	129 (16)
WHO performance status
WHO 0	262 (33)
WHO 1	448 (56)
WHO 2	83 (10)
WHO 3	2 (0.2)
Bone marrow cellularity
Low	60 (7)
Medium	123 (15)
High	430 (53)
WBC count (× 10^9 cells/L)
1st quantile	2
Median	5.5
3rd quantile	27
Prior haematological or oncological disease
No	747 (93)
Yes	59 (7)
Previous chemo- or radiotherapy
No	596 (74)
Yes	210 (26)
Bone marrow fibrosis
No	497 (62)
Yes	112 (14)

AML acute myeloid leukaemia, MDS myelodysplastic syndrome, WBC white blood cell. Unknown entry is not displayed
The HOVON trial included 866 patients of whom 60 were excluded from the analysis. Patients were excluded from the analysis for the following reasons: incomplete records (n = 33), time of diagnosis and or time of follow-up not documented correctly (n = 8), registered twice (n = 4), missing informed consent (n = 1), diagnosis of acute promyelocytic leukaemia (n = 6), no AML (n = 4), diagnosis of refractory anaemia with an international prognostic score of less than 1.5 (low-risk MDS) (n = 1), previously treated AML (n = 1), medical history of malignant lymphoma (n = 1) or concurrent liver cancer (n = 1)

ISSN: 1471-2334